Tumor Necrosis Factor- α Inhibitors in Cardiac Sarcoidosis Management: Evaluating Therapeutic Efficacy and Future Directions

Cardiac sarcoidosis (CS) is a clinically challenging manifestation of systemic sarcoidosis, which is an idiopathic inflammatory disorder pathologically distinguished by non –caseating granulomas. Advanced cardiac imaging estimates approximately 30% of patients diagnosed with systemic sarcoidosis have cardiac involvement, with a primary presentation of heart failure, complete heart block, or ventricular arrhythmias.1,2 The past decades have seen a>20-fold increase in CS detection, emphasizing its escalating clinical significance.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research